Published in MAbs on January 13, 2010
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Small molecule inhibitors of CXCR4. Theranostics (2013) 1.30
Improvements to the Kunkel mutagenesis protocol for constructing primary and secondary phage-display libraries. Methods (2012) 0.84
A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation. PLoS One (2012) 0.78
Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. J Biol Chem (2011) 0.77
Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase. PLoS One (2016) 0.75
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol (2003) 6.59
Antibody multispecificity mediated by conformational diversity. Science (2003) 5.21
Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol (1996) 4.45
Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol (2007) 3.43
Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat Biotechnol (2000) 3.06
Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol (2002) 2.88
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest (1999) 2.16
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol (1996) 2.08
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A (1994) 1.93
Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology (2007) 1.79
Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol (2003) 1.52
Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel (2008) 1.45
Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem (2002) 1.28
Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol (2001) 1.27
IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res (2003) 1.21
CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res (2008) 1.11
Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J Immunol (2007) 1.10
Manufacture of recombinant polyclonal antibodies. Biotechnol Lett (2007) 1.06
CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J Immune Based Ther Vaccines (2008) 1.04
Chemokine inhibition--why, when, where, which and how? Biochem Soc Trans (2004) 1.02
A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med (2007) 0.97
Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. Protein Eng Des Sel (2006) 0.96
Chemokines derived from soluble fusion proteins expressed in Escherichia coli are biologically active. Biochem Biophys Res Commun (2005) 0.88
Antibody engineering for therapeutics. Curr Opin Struct Biol (2003) 0.84
In vivo imaging of germinal centres reveals a dynamic open structure. Nature (2007) 3.83
Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A (2003) 3.77
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest (2007) 3.28
Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity (2002) 2.47
Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity (2005) 1.86
Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med (2008) 1.65
Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol (2004) 1.39
Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood (2002) 1.37
CCR7 is involved in the migration of neutrophils to lymph nodes. Blood (2010) 1.34
The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J Immunol (2002) 1.28
Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies. Vaccine (2002) 1.20
The follicular dendritic cell restricted epitope, FDC-M2, is complement C4; localization of immune complexes in mouse tissues. Eur J Immunol (2002) 1.19
Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity (2010) 1.15
Deep sequencing of phage display libraries to support antibody discovery. Methods (2013) 1.11
Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J Immunol Methods (2003) 1.10
Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology (2008) 1.03
The generation of thymus-independent germinal centers depends on CD40 but not on CD154, the T cell-derived CD40-ligand. Eur J Immunol (2006) 1.01
IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J Immunol (2002) 0.99
CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J (2011) 0.98
Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis. J Immunol (2010) 0.97
Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol (2010) 0.96
Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs. Eur J Immunol (2003) 0.90
The scavenger receptors SRA-1 and SREC-I cooperate with TLR2 in the recognition of the hepatitis C virus non-structural protein 3 by dendritic cells. J Hepatol (2010) 0.89
Chemokines derived from soluble fusion proteins expressed in Escherichia coli are biologically active. Biochem Biophys Res Commun (2005) 0.88
Transferring the characteristics of naturally occurring and biased antibody repertoires to human antibody libraries by trapping CDRH3 sequences. PLoS One (2012) 0.88
The ferredoxin docking site of photosystem I. Biochim Biophys Acta (2002) 0.88
Critical role of cPLA2 in Aβ oligomer-induced neurodegeneration and memory deficit. Neurobiol Aging (2011) 0.86
IL-18 binding protein protects against contact hypersensitivity. J Immunol (2003) 0.86
Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods (2011) 0.85
Homing of human B cells to lymphoid organs and B-cell lymphoma engraftment are controlled by cell adhesion molecule JAM-C. Cancer Res (2012) 0.85
IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS. Am J Pathol (2004) 0.83
De novo isolation of antibodies with pH-dependent binding properties. MAbs (2015) 0.81
Cardiotrophin-like cytokine labelling using Bir A biotin ligase: a sensitive tool to study receptor expression by immune and non-immune cells. J Immunol Methods (2005) 0.81
Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol (2014) 0.81
Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies. MAbs (2013) 0.79
Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. J Biol Chem (2011) 0.77
Smarter drugs: a focus on pan-specific monoclonal antibodies. BioDrugs (2011) 0.77
Rapid, simple and high yield production of recombinant proteins in mammalian cells using a versatile episomal system. Protein Expr Purif (2010) 0.76
Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors. MAbs (2014) 0.75
Rapid purification of monoclonal antibodies using magnetic microspheres. Methods Mol Biol (2014) 0.75
Extracellular lysosome-associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the NOD model of type 1 diabetes. Eur J Immunol (2005) 0.75